Related Experiment Video
Updated: Nov 1, 2025
Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
Published on: November 29, 2024
Role of novel biomarkers in diabetic cardiomyopathy
Marko Kumric1, Tina Ticinovic Kurir1, Josip A Borovac1
1Department of Pathophysiology, University of Split School of Medicine, Split 21000, Croatia.
Insights
Diabetic cardiomyopathy (DCM) detection can be improved using novel biomarkers like long noncoding RNAs, sST2, and galectin-3. Combining these with echocardiography may aid early screening in diabetes patients.
Area of Science:
- Biomarkers and cardiovascular disease research.
- Endocrinology and metabolic disorders.
- Molecular diagnostics in cardiology.
Background:
- Diabetic cardiomyopathy (DCM) is a significant complication of diabetes mellitus, often underdiagnosed.
- Current diagnostic methods for DCM are insufficient, leading to poor patient outcomes.
- There is a critical need for reliable biomarkers for early DCM detection and management.
Purpose of the Study:
- To review potential biomarkers for the early detection of diabetic cardiomyopathy.
- To evaluate the efficacy of long noncoding RNAs, sST2, and galectin-3 in DCM diagnosis.
- To explore the utility of combining imaging techniques with biomarkers for DCM screening.
Main Methods:
- Comprehensive analysis of existing human and animal studies on DCM biomarkers.
- Assessment of plasma/serum levels of long noncoding RNAs, soluble form of suppression of tumorigenicity 2 (sST2), and galectin-3.
- Evaluation of speckle tracking echocardiography in conjunction with biomarker analysis.
Main Results:
- Long noncoding RNAs, sST2, and galectin-3 show strong correlation with early-stage DCM.
- Plasma/serum levels of these biomarkers accurately reflect DCM progression.
- Speckle tracking echocardiography combined with biomarkers offers a promising screening approach.
Conclusions:
- Long noncoding RNAs, sST2, and galectin-3 are promising biomarkers for DCM detection.
- A combined screening approach using echocardiography and biomarkers can identify at-risk diabetes patients.
- Early detection and management are crucial for mitigating DCM's poor outcomes, aligning with interdisciplinary care guidelines.
Abstract:
Diabetic cardiomyopathy (DCM) is commonly defined as cardiomyopathy in patients with diabetes mellitus in the absence of coronary artery disease and hypertension. As DCM is now recognized as a cause of substantial morbidity and mortality among patients with diabetes mellitus and clinical diagnosis is still inappropriate, various expert groups struggled to identify a suitable biomarker that will help in the recognition and management of DCM, with little success so far. Hence, we thought it important to address the role of biomarkers that have shown potential in either human or animal studies and which could eventually result in mitigating the poor outcomes of DCM. Among the array of biomarkers we thoroughly analyzed, long noncoding ribonucleic acids, soluble form of suppression of tumorigenicity 2 and galectin-3 seem to be most beneficial for DCM detection, as their plasma/serum levels accurately correlate with the early stages of DCM. The combination of relatively inexpensive and accurate speckle tracking echocardiography with some of the highlighted biomarkers may be a promising screening method for newly diagnosed diabetes mellitus type 2 patients. The purpose of the screening test would be to direct affected patients to more specific confirmation tests. This perspective is in concordance with current guidelines that accentuate the importance of an interdisciplinary team-based approach.
More Related Videos
05:58Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model
Published on: April 18, 2025
11:00Assessment of Sarcoplasmic Reticulum Calcium Reserve and Intracellular Diastolic Calcium Removal in Isolated Ventricular Cardiomyocytes
Published on: September 18, 2017
Related Concept Videos
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
01:30Cardiomyopathy II: Dilated Cardiomyopathy
01:30Coronary Artery Disease I: Introduction
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
01:29Cardiomyopathy IV: Restrictive Cardiomyopathy